Hereditary Prostate Cancer Testing
REFERENCE GUIDE

There is no room for doubt when it comes to making important life impacting healthcare decisions. By providing advanced confirmation genetic testing for hereditary prostate cancer, we can help you make more informed and reliable healthcare decisions with your patients.

The more accurate the results, the more insight you have to better treat your patients.

American Society of Clinical Oncology (ASCO)

ASCO recommends that genetic testing be offered to individuals with suspected inherited (genetic) cancer risk in situations where test results can be interpreted, and when they affect medical management of the patient. It is sufficient for cancer risk assessment to evaluate genes of established clinical utility that are suggested by the patient’s personal and/or family history.

Adapted from J Clin Oncol., 2015.

Why Is Genetic Testing Important?

**KEY BENEFITS**

Identifying patients with a genetic predisposition to cancer can allow informed recommendations and personalized medical management that significantly decrease cancer risks and improve overall survival rates.

- Option to modify frequency and initial age of prostate cancer screening
- Consideration of risk-reducing measures for your patient and/or their family members
- Option to tailor treatments (e.g. PARP inhibitors for prostate cancer patients who have ATM or BRCA1/BRCA2 mutations)
- Identify at-risk family members
Identify Patients Who May Need Genetic Testing

If your patient or their family members have any of the following signs* for hereditary cancer, consider genetic testing:

- **Multiple**: 2 or more primary cancers in the same person
- **Young**: Any of the following cancers diagnosed <50 years: Prostate, breast (female), colorectal, uterine
- **Rare**: Male breast cancer, ovarian cancer, pancreatic cancer
- **Metastatic**: Metastatic prostate cancer at any age

* Adapted from published genetic testing guidelines

Known Causes of Hereditary Prostate Cancer

**ORDERING THE RIGHT TEST CAN PROVIDE THE MOST ACCURATE AND COMPREHENSIVE ANSWERS**

Over 180,000 cases of prostate cancer are diagnosed each year. It is currently thought that 5-10% of those will be hereditary. BRCA1/2 only tells half the story.

Previous studies have shown 4.6-11.8% detection rates of germline mutations in men diagnosed with low grade and metastatic prostate cancer, respectively.\(^1\)\(^2\) However, Ambry internal data suggests the detection rate could be as high as 14%, and the most common germline gene mutations identified are in BRCA2, ATM, HOXB13, and CHEK2.\(^3\)

Additionally, our study of >34,000 individuals revealed that 22% of patients identified to have Lynch syndrome, only met NCCN\(^8\) guidelines for BRCA1/2 genetic testing.\(^4\) Therefore, multigene panel testing may identify potentially unexpected hereditary cancer syndromes, which may have significant implications for medical management.

---

Finding Answers Through Quality Genetic Testing

Ambry’s hereditary prostate cancer testing options:

<table>
<thead>
<tr>
<th>Test</th>
<th>Description</th>
<th>Average Turnaround Time*</th>
</tr>
</thead>
<tbody>
<tr>
<td>ProstateNext</td>
<td>Clear results to guide treatment decisions and offer more information to identify and manage hereditary prostate cancer NCCN® management guidelines available for most genes</td>
<td>11.8 calendar days</td>
</tr>
<tr>
<td>CancerNext</td>
<td>Comprehensive panel covering a broad range of tumor types, giving you more information to make better treatment and management decisions NCCN® management guidelines available for most genes</td>
<td>11.5 calendar days</td>
</tr>
</tbody>
</table>

* Ambry’s turnaround time represents the time that it takes for Ambry to perform the requested testing. When all necessary clinical and family history information is provided with the sample, results are typically completed within 14 days. We will notify you in the unusual event that results will take longer than 21 days.

LEARN MORE about your patient’s prostate cancer risk by opting into AmbryScore, an individualized prostate cancer risk calculation. AmbryScore is available with select multigene panels, including ProstateNext and CancerNext, for eligible patients. Visit our website for more detailed information and eligibility criteria: ambrygen.com/ambryscore

Prostate Cancer Genes and Associated Risks

Potential lifetime cancer risks for patients with a hereditary cancer syndrome

General population

* Lynch genes: MLH1, MSH2, MSH6, PMS2, EPCAM

Ambry continually participates in important game-changing studies to expand our knowledge of hereditary cancers. Please visit our website to see the most updated lists of genes included on our panels and additional testing options available: ambrygen.com/hereditary-cancer-panels
Purposeful Confirmatory Testing

Many labs validate their tests based on certain limited studies. That’s why we participated and led the largest study of its kind (20,000 cases) guiding us to utilize confirmatory testing when we see specific well-defined thresholds. Our mission is to get it right the first time.

Understanding Disease Better Through Free Data Sharing

Identifying an individual's genetic information is nothing new—it’s what we do with it that is unique. When labs share genomic information, we can together accelerate the understanding of human disease. Through AmbryShare, we leverage de-identified information to collaborate with others and help people everywhere find answers.

Free Testing for Family Members

We offer specific site analysis (SSA) at no additional cost for family members following single gene or multigene panel testing of the first family member (proband) within 90 days of the original Ambry report date.

Ambry’s Translational Genomics (ATG) Lab

As an advanced diagnostic lab, it’s our responsibility to ensure the results you get from us are accurate and that classification is as complete and robust as possible. Our ATG lab is a unique laboratory that provides an additional service at no additional cost for you and your patients to generate more precise data potentially bringing clarity to some variants of unknown significance (VUS). This helps to actively drive down the rate of VUS results and can give you an increased understanding of your patient’s results, so you can better provide medical management recommendations and improve health outcomes.

About Ambry

Just as no two fingerprints are alike, the way disease presents itself in every individual is different. Since 1999, our mission has always been about understanding disease better, so treatments and cures can be found faster. Every sample that arrives in our lab is viewed as a person with a life and a story that is unique to only them. By providing advanced confirmation genetic testing for inherited and non-inherited diseases, we can help you make more informed and responsible treatment decisions with your patients.